With 1,500 active life sciences companies and a vibrant research and innovation ecosystem, it’s hardly surprising that Israel is at the center of some of the most important developments in health and medical technology.
That holds true in burgeoning fields like digital health and AI-driven medicine, and it’s no less true for an established industry like pharmaceuticals. Not only is Israel home to Teva Pharmaceutical Industries, which dates to the turn of the 20th century and is the globe’s top generic drug manufacturer, the country has also given rise to a diverse array of biotechnology companies, R&D centers, and prestigious academic institutions, putting Israeli ingenuity at the forefront of treatment discovery and development.
Doxil (known as Caelyx in Europe and Canada), the world’s first nano-medicine for treating various types of cancer, was developed by researchers at the Hebrew University of Jerusalem. The Weizmann Institute of Science incubated groundbreaking multiple sclerosis drug Copaxone, among the first Israeli medications to receive approval from the U.S. Food and Drug Administration. Recent decades have seen Israel become an even more integral part of the global pharmaceutical industry, with exports to the U.S. alone climbing from $208 million in 1997 to $5.9 billion in 2018.
Here’s a look at just a few of the innovative companies on the Israeli pharmaceutical landscape:
What does the future hold in store for the Israeli pharmaceutical industry? With emerging fields like personalized treatment and AI-based drug discovery set to transform modern medicine, Israel is well-positioned to continue playing a vital role in pharmaceutical innovation thanks to its well-developed strength in these and other high-tech fields – with countless lives saved in the process.
For more information, please visit http://www.itrade.gov.il/ or contact your local Israel Economic Attaché.